



wherein A represents any one of the structures of formula (2):



or a pharmaceutically acceptable salt thereof, and (b) at least one additive selected from the group consisting of an excipient, a disintegrant, a binder, a lubricant, a coating agent and a solvent.

19. The pharmaceutical composition according to claim 18, wherein said benzamide derivative is represented by formula (3):



20. The pharmaceutical composition according to claim 18, wherein said excipient is D-mannitol.

21. The pharmaceutical composition according to claim 18, wherein said disintegrant is at

least one disintegrant selected from the group consisting of partly pregelatinized starch, carmellose calcium, and carboxymethylstarch sodium.

22. The pharmaceutical composition according to claim 18, wherein said binder is hydroxypropyl cellulose.

23. The pharmaceutical composition according to claim 18, wherein said lubricant is at least one lubricant selected from the group consisting of magnesium stearate and talc.

24. The pharmaceutical composition according to claim 18, wherein said coating agent is hydroxypropyl methylcellulose.

25. The pharmaceutical composition according to claim 18, wherein said solvent is at least one solvent selected from the group consisting of a propylene glycol, dimethylacetamide, and polyethylene glycol.

26. The pharmaceutical composition according to claim 18, further comprising at least one compound selected from the group consisting of an organic acid salt, an amino compound, and an inorganic basic substance.

27. The pharmaceutical composition according to claim 26, wherein said organic acid salt is at least one organic acid salt selected from the group consisting of monosodium fumarate, sodium alginate, sodium dehydroacetate, sodium erythorbate, and trisodium citrate.

28. The pharmaceutical composition according to claim 26, wherein said amino compound is at least one amino compound selected from the group consisting of tris(hydroxymethyl)aminomethane, monoethanolamine, diethanolamine, triethanolamine, diisopropanolamine, triisopropanolamine, dihydroxyaluminum aminoacetate, arginine, creatinine, sodium glutamate, glycine, L-arginine, L-glutamate, and carbachol.

29. The pharmaceutical composition according to claim 26, wherein said inorganic basic substance is at least one inorganic basic substance selected from the group consisting of sodium carbonate, potassium carbonate, ammonium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydroxide, disodium phosphate, and ammonia.

30. The pharmaceutical composition according to any one of claims 18-29, wherein the pharmaceutical composition is a solid composition which comprises granules prepared by a dry granulation method.

31. The pharmaceutical composition according to any one of claims 18-29, wherein the pharmaceutical composition is a liquid composition with an adjusted pH ranging from about 4 to about 12.

1004-9446-021502